Search results for "Lung"

showing 10 items of 2389 documents

Translocation (X;18) in a Biphasic Synovial Sarcoma with Morphologic Features of Neural Differentiation

1998

The authors report a recurred neoplasm showing distinctive histologic, immunophenotypic, and ultrastructural features characteristic of biphasic synovial sarcoma with neural differentiation. The features include areas with a growth pattern of densely packed spindle cells in irregularly intersecting, broad fascicles, diffuse vimentin and HBA 71 immunoreactivity, expression of S-100 protein, and other neural markers. Moreover, areas with glandular structures and cellular expression of cytokeratin and epithelial membrane antigen were noted. Additionally, areas of neural-like growth pattern were positive for neuron-specific enolase, HNK-1, and protein gene product 9.5. Furthermore, cytogenetic …

AdultMaleLung NeoplasmsX ChromosomeBiphasic Synovial SarcomaEnolaseSoft Tissue NeoplasmsChromosomal translocationVimentinPolymerase Chain ReactionTranslocation GeneticImmunophenotypingPathology and Forensic MedicineGene productSarcoma SynovialCytokeratinTumor Cells CulturedmedicineHumansMolecular BiologyIn Situ Hybridization FluorescenceNeuronsmedicine.diagnostic_testbiologyChemistryCell DifferentiationPatellaCell BiologyMolecular biologyReverse transcription polymerase chain reactionKaryotypingbiology.proteinChromosomes Human Pair 18Fluorescence in situ hybridizationDiagnostic Molecular Pathology
researchProduct

Nuclear magnetic resonance imaging with hyperpolarised helium-3

1996

Abstract Summary Background Magnetic resonance imaging (MRI) relies on magnetisation of hydrogen nuclei (protons) of water molecules in tissue as source of the signal. This technique has been valuable for studying tissues that contain significant amounts of water, but biological settings with low proton content, notably the lungs, are difficult to image. We report use of spin-polarised helium-3 for lung MRI. Methods A volunteer inhaled hyperpolarised 3 He to fill the lungs, which were imaged with a conventional MRI detector assembly. The nuclear spin polarisation of helium, and other noble gases, can be greatly enhanced by laser optical pumping and is about 10 5 times larger than the polari…

AdultMaleMaterials sciencemedicine.diagnostic_testProtonSpin polarizationchemistry.chemical_elementMagnetic resonance imagingGeneral MedicineHyperpolarized Helium 3LaserHeliumMagnetic Resonance Imaginglaw.inventionNuclear magnetic resonanceIsotopeschemistrylawHelium-3medicineHumansHyperpolarization (physics)LungHeliumThe Lancet
researchProduct

Acrometastases to the Hand: A Systematic Review

2021

Background and Objectives: The term acrometastases (AM) refers to secondary lesions sited distally to the elbow and knee, representing 0.1% of all bony metastases. By frequency, pulmonary cancer and gastrointestinal and genitourinary tract neoplasms are the most responsible for the reported AM. Improvements in oncologic patient care favor an increase in the incidence of such rare cases. We performed a systematic review of acrometastases to the hand to provide further insight into the management of these fragile patients. We also present a peculiar case of simultaneous acrometastasis to the ring finger and pathological vertebral fracture. Material and Methods: A literature search according t…

AdultMaleMedicine (General)medicine.medical_specialtyLung NeoplasmsAdolescentmedicine.medical_treatmentBone NeoplasmsWristMetastasisFingersYoung AdultFinger PhalangesR5-920Breast cancerThumb metastasesmedicineCarcinomaChemotherapyHumansChildAgedAged 80 and overRadiotherapyAcrometastasesbusiness.industryGenitourinary systemIncidence (epidemiology)CarcinomaAcrometastases; Carcinoma; Chemotherapy; Immunotherapy; Radiotherapy; Thumb metastases; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Fingers; Humans; Male; Middle Aged; Prognosis; Young Adult; Bone Neoplasms; Finger Phalanges; Lung NeoplasmsGeneral MedicineMiddle AgedPrognosismedicine.diseasePrimary tumorRadiation therapymedicine.anatomical_structureFemaleSystematic ReviewImmunotherapyRadiologybusinessMedicina
researchProduct

Quantification of Regional Intrapulmonary Oxygen Partial Pressure Evolution during Apnea by 3He MRI

1999

We present a new method to determine in vivo the temporal evolution of intrapulmonary oxygen concentrations by functional lung imaging with hyperpolarized (3)Helium ((3)He-->). Single-breath, single-bolus visualization of (3)He--> administered to the airspaces is used to analyze nuclear spin relaxation caused by the local oxygen partial pressure p(O(2))(t). We model the dynamics of hyperpolarization in the lung by rate equations. Based hereupon, a double acquisition technique is presented to separate depolarization by RF pulses and oxygen induced relaxation. It permits the determination of p(O(2)) with a high accuracy of up to 3% with simultaneous flip angle calibration using no additional …

AdultMaleNuclear and High Energy PhysicsApneaSwinePartial PressureBiophysicsAnalytical chemistrychemistry.chemical_elementHyperpolarized Helium 3HeliumBiochemistryOxygenNuclear magnetic resonanceIsotopesFlip angleAnimalsHumansHyperpolarization (physics)LungPhantoms ImagingRelaxation (NMR)DepolarizationPartial pressureCondensed Matter PhysicsMagnetic Resonance ImagingOxygenchemistryLimiting oxygen concentrationJournal of Magnetic Resonance
researchProduct

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer

2005

<i>Background:</i> Induction chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials. <i>Patients and Methods:</i> In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy. <i>Results:</i> Objective response (4 complete remission and 36 partial remission) was achieved i…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentDeoxycytidineAntimetaboliteDisease-Free SurvivalDrug Administration ScheduleCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedNeoplasm StagingChemotherapybusiness.industryRemission InductionInduction chemotherapyLung cancer Paclitaxel Carboplatin stage III ChemotherapyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineCarboplatinrespiratory tract diseasesSurgeryRadiation therapyTreatment OutcomeOncologychemistryPaclitaxelChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinessmedicine.drug
researchProduct

Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

2014

Chronic obstructive pulmonary disease (COPD) and lung cancer are widespread lung diseases. Cigarette smoking is a high risk factor for both the diseases. COPD may increase the risk of developing lung cancer. Thus, it is crucial to be able to distinguish between these two pathological states, especially considering the early stages of lung cancer. Novel diagnostic and monitoring tools are required to properly determine lung cancer progression because this information directly impacts the type of the treatment prescribed. In this study, serum samples collected from 22 COPD and 77 lung cancer (TNM stages I, II, III, and IV) patients were analyzed. Then, a collection of NMR metabolic fingerprin…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsMagnetic Resonance SpectroscopyClinical BiochemistryPharmaceutical ScienceCreatineAnalytical ChemistryDiagnosis DifferentialPulmonary Disease Chronic Obstructivechemistry.chemical_compoundPredictive Value of TestsCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansMetabolomicsLeast-Squares AnalysisRisk factorLung cancerLungPathologicalEarly Detection of CancerSpectroscopyAgedNeoplasm StagingAged 80 and overUnivariate analysisCOPDLungChemistryDiscriminant AnalysisMiddle AgedPrognosismedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureMultivariate AnalysisDisease ProgressionFemaleLung cancer stagingJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

2005

Summary Background Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods We analysed data for 1265 patients who received chemotherapy (vinorelbine, gemcitabine, gemcitabine and vinorelbine, cisplatin and vinorelbine, or cisplatin and gemcitabine) within three randomised trials. Primary landmark analyses were restricted to 436 patients who received all six planned chemotherapy cycles and who were alive 180 days after randomisation. Neutropenia was categorised on the basis of worst WHO g…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentAntineoplastic AgentsNeutropenia.VinorelbineSeverity of Illness IndexCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansLung cancerSurvival rateAgedProportional Hazards ModelsRandomized Controlled Trials as TopicAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryStandard treatmentHazard ratioMiddle Agedrandomized clinical trialmedicine.diseaseGemcitabineSurgerySurvival Ratelandmark analysisnon-small-cell lung cancerItalyOncologychemotherapy-induced neutropeniaFemaleDrug MonitoringbusinessBiomarkersmedicine.drug
researchProduct

Translocation (11;22) in small cell osteosarcoma

1990

AdultMaleOsteosarcomaCancer Researchmedicine.medical_specialtyLung NeoplasmsChromosomes Human Pair 11Chromosomes Human Pair 22CytogeneticsBone NeoplasmsKaryotypeChromosomal translocationBiologymedicine.diseaseMolecular biologyTranslocation GeneticSmall Cell OsteosarcomaScapulaKaryotypingGeneticsmedicineHumansOsteosarcomaMolecular BiologyCancer Genetics and Cytogenetics
researchProduct